About PuriSpec
Built on Deep Expertise in Synthesis, Separation, and Drug Discovery
PuriSpec was founded by scientists with decades of pharmaceutical and biotechnology experience, united by a commitment to advancing drug development through precision chromatographic and spectroscopic solutions.
Our Story
PuriSpec, LLC was founded in 2011 with a singular focus: applying supercritical fluid chromatography and mass spectrometry to the purification and spectroscopic analysis of diverse compound sets across drug discovery and chemical development.
From early-stage lead identification to scale-up and commercial manufacturing support, PuriSpec partners with pharmaceutical and biotechnology companies to deliver the purified, well-characterized material their programs depend on.
Leadership
Meet the Founder
Dr. Douglas A. Pippin
Founder, President & CEO — PuriSpec, LLC/ Praeventix, Inc
- B.Sc. Chemistry — Central Connecticut State University, 1996
- Ph.D. Synthetic Organic Chemistry — Dartmouth College, 2001
- Senior Research Scientist — CGI Pharmaceuticals (2002–2005)
- Research Scientist — Cephalon, Inc. (2005–2009)
- Founder — TransSig, Inc. (2009–present)
- Founder & President— PuriSpec, LLC (2011–present)
- Founder & President — Theraceutix, LLC (2012–present)
- Founder & President — Praeventix, Inc. (2015–present)
- Board Member — TransSig, Inc. / PuriSpec, LLC / Theraceutix, LLC / Praeventix, Inc.
- >100 global patents (issued/pending) · 18 scientific publications
Dr. Pippin received his B.Sc. degree in Chemistry from Central Connecticut State University in 1996 and his Ph.D. in Synthetic Organic Chemistry in 2001 from Dartmouth College under the guidance of Professor Peter A. Jacobi.
In 2002, he joined CGI Pharmaceuticals as a Senior Research Scientist where he led high-throughput medicinal chemistry efforts in early lead identification and lead optimization of targeted kinase programs in oncology and autoimmune/anti-inflammatory disease.
In 2005, Dr. Pippin joined Cephalon, Inc. where he continued his work in the investigation of agents for treatment of cellular proliferation and CNS disorders.
In 2009, he founded TransSig, Inc.; as its President and CEO, Dr. Pippin continues to focus on the discovery, development, and marketing of novel multi-target signal transduction modulating agents for the treatment of cellular proliferation disorders in unmet clinical needs.
In 2011, he co-founded PuriSpec, LLC — a company focused on the spectrographic analysis and purification of diverse sets of compounds for numerous applications in drug discovery, with the use of supercritical fluid chromatography/mass spectrometry (SFC/MS).
In 2015, he founded Praeventix, Inc. — a development stage biopharmaceutical company committed to the discovery, research and clinical development of novel serotonergic therapeutics with potential applications in dermatologic, autoimmune and neurodegenerative diseases.
Dr. Pippin currently sits on the board of four privately-held biotechnology firms: TransSig, Inc., PuriSpec, LLC, Theraceutix, LLC, and Praeventix, Inc. He is an inventor, medicinal chemist and executive with a global estate of over 100 issued patents and pending applications across the U.S., Europe, and Asia, protecting breakthroughs in oncology, inflammation, and neurodegenerative diseases and an author of 18 scientific publications and review articles.
What Drives Us
Scientific Rigor
Every separation, synthesis, and characterization is executed with meticulous attention to detail and full analytical documentation.
Partnership Mindset
We work as an extension of your team — responsive, transparent, and aligned with your project timelines and regulatory requirements.
Green Chemistry
Our SFC-first approach dramatically reduces solvent consumption compared to traditional HPLC, reflecting our commitment to sustainable science.
Breadth of Expertise
From chiral building blocks to multi-gram preparative purification, our capabilities span the full drug development continuum.
Partner With PuriSpec
Whether you need a single chiral separation or a long-term synthesis and purification partner, we are ready to discuss your project.